PARP inhibitor Clinical Trials
4 recruitingDrug
Phase 24Phase 31
Showing 1–4 of 4 trials
Recruiting
Phase 2
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Salivary Gland CarcinomaPrecision Therapy
Peking Union Medical College39 enrolled2 locationsNCT06145308
Recruiting
Phase 2Phase 3
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancers
N.N. Alexandrov National Cancer Centre120 enrolled1 locationNCT07472140
Recruiting
Phase 2
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
Shanghai Gynecologic Oncology Group220 enrolled9 locationsNCT05200260
Recruiting
Phase 2
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Neoadjuvant Therapy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School900 enrolled1 locationNCT05406999